Q3 Revenue Jumps 49% to $10.2M, Full-Year Guidance Raised to at Least $34.5M
MXCT has more than doubled off its 52-week low of $0.643.
Summary
MaxCyte posted Q3 2026 total revenue of $10.2 million, up 49% from a year ago, with core revenue of $8.2 million up 27% and SPL program revenue of $2.0 million versus $0.4 million. The net loss narrowed to $4.8 million from $12.4 million as operating expenses fell to $14.5 million from $19.4 million. Management raised full-year 2026 total revenue guidance to at least $34.5 million, implying a return to full-year growth, split between roughly $28 million core and at least $6.5 million SPL, and expects roughly 15% core growth in the second half. The company held $132.7 million in cash and investments at quarter-end, though it expects $40-45 million by year-end after paying about $105 million in cash for Akron Bio plus deal costs, with $22 million drawn on the MidCap facility. The Akron acquisition announced this morning is the bigger story; these results show the standalone business accelerating into the deal.
At the time of this announcement, MXCT was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $134.2M. The 52-week trading range was $0.64 to $1.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.